156 related articles for article (PubMed ID: 37982667)
21. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Lowe G; Costabile RA
J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis.
Mykoniatis I; Pyrgidis N; Sokolakis I; Ouranidis A; Sountoulides P; Haidich AB; van Renterghem K; Hatzichristodoulou G; Hatzichristou D
JAMA Netw Open; 2021 Feb; 4(2):e2036337. PubMed ID: 33599772
[TBL] [Abstract][Full Text] [Related]
23. Spectroscopic determination of hydrophobic adulterant tadalafil by aptasensor based ellipsometry.
Üstündağ İ; Caglayan MO
Talanta; 2024 Jan; 266(Pt 1):124940. PubMed ID: 37454513
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
[TBL] [Abstract][Full Text] [Related]
25. The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews.
Pyrgidis N; Mykoniatis I; Haidich AB; Tirta M; Talimtzi P; Kalyvianakis D; Ouranidis A; Hatzichristou D
Front Pharmacol; 2021; 12():735708. PubMed ID: 34557099
[No Abstract] [Full Text] [Related]
26. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.
Feng S; Zhou L; Liu Q; He Q; Liao B; Wei X; Li H; Wang K; Zhu Y
Medicine (Baltimore); 2018 Jan; 97(3):e9601. PubMed ID: 29504984
[TBL] [Abstract][Full Text] [Related]
27. Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.
Tsai WK; Jiann BP
Int J Impot Res; 2014; 26(4):141-5. PubMed ID: 24451166
[TBL] [Abstract][Full Text] [Related]
28. Current use of phosphodiesterase inhibitors in urology.
Hakky TS; Jain L
Turk J Urol; 2015 Jun; 41(2):88-92. PubMed ID: 26328208
[TBL] [Abstract][Full Text] [Related]
29. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
30. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
[TBL] [Abstract][Full Text] [Related]
31. No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma.
Wang JZ; Le S; Alexanian C; Boddu S; Merleev A; Marusina A; Maverakis E
World J Mens Health; 2019 Sep; 37(3):313-321. PubMed ID: 30350485
[TBL] [Abstract][Full Text] [Related]
32. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
Herlemann A; Gratzke C; Andersson KE; Sievert KD
Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
[TBL] [Abstract][Full Text] [Related]
33. Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
Tang H; Wu W; Fu S; Zhai S; Song Y; Han J
J Am Acad Dermatol; 2017 Sep; 77(3):480-488.e9. PubMed ID: 28728871
[TBL] [Abstract][Full Text] [Related]
34. New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is).
Ribaudo G; Pagano MA; Bova S; Zagotto G
Curr Med Chem; 2016; 23(12):1239-49. PubMed ID: 27121186
[TBL] [Abstract][Full Text] [Related]
35. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
Chen JJ; Sun YL; Tiwari AK; Xiao ZJ; Sodani K; Yang DH; Vispute SG; Jiang WQ; Chen SD; Chen ZS
Cancer Sci; 2012 Aug; 103(8):1531-7. PubMed ID: 22578167
[TBL] [Abstract][Full Text] [Related]
36. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
[TBL] [Abstract][Full Text] [Related]
37. A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients.
Natali A; Masieri L; Lanciotti M; Giancane S; Vignolini G; Carini M; Serni S
Int J Impot Res; 2015; 27(1):1-5. PubMed ID: 25056808
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
García-Perdomo HA; Echeverría-García F; Tobías A
Urol Int; 2017; 98(2):198-204. PubMed ID: 27509143
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase type 5 inhibitor abuse: a critical review.
Lowe G; Costabile R
Curr Drug Abuse Rev; 2011 Jun; 4(2):87-94. PubMed ID: 21696344
[TBL] [Abstract][Full Text] [Related]
40. Lodenafil.
Alshehri YM; Al-Majed AA; Attwa MW; Bakheit AH
Profiles Drug Subst Excip Relat Methodol; 2022; 47():113-147. PubMed ID: 35396013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
